@article{9ac57e5c69e1408d85b75127a195d42a,
title = "An algorithm for the management of restless legs syndrome",
abstract = "Restless legs syndrome (RLS) is a common disorder with a prevalence of 5% to 15%. Primary care physicians must become familiar with management of this disorder. This algorithm for the management of RLS was written by members of the Medical Advisory Board of the Restless Legs Syndrome Foundation and is based on scientific evidence and expert opinion. Restless legs syndrome is divided into intermittent, daily, and refractory types. Nonpharmacological approaches, including mental alerting activities, avoiding substances or medications that may exacerbate RLS, and addressing the possibility of iron deficiency, are discussed. The role of carbidopa/levodopa, dopamine agonists, opioids, benzodiazepines, and anticonvulsants for the different types of the disorder is delineated.",
keywords = "CR = controlled release, MAB = medical advisory board, RLS = restless legs syndrome",
author = "Silber, {Michael H.} and Ehrenberg, {Bruce L.} and Allen, {Richard P.} and Buchfuhrer, {Mark J.} and Earley, {Christopher J.} and Hening, {Wayne A.} and Rye, {David B.}",
note = "Funding Information: These considerations led the medical advisory board (MAB) of the nonprofit Restless Legs Syndrome Foundation to attempt the construction of an algorithm for the management of RLS. The effort was supported by the Board of Directors of the Restless Legs Syndrome Foundation, but this article is entirely the work of the physicians and scientists on the MAB. A task force of the MAB produced and revised a draft that was submitted for approval to the other members of the board. The authors have had many years of experience in the treatment of RLS in either academic or primary care settings and have conducted original research on this disorder. Some have been members of task forces that have produced the previously discussed evidence-based reviews. Funding Information: The authors were not paid to produce this algorithm. Dr Ehrenberg has received patent royalties from Ortho-McNeil Pharmaceutical and is a part-time consultant for Boehringer Ingelheim Corporation. Dr Allen has served as a consultant and/or received travel grants from Boehringer Ingelheim Corporation, GlaxoSmithKline, Pfizer, Inc, and Sepracor, Inc. Dr Buchfuhrer has had a research grant from GlaxoSmithKline. Dr Hening has served as a consultant and/or received travel grants from GlaxoSmithKline, Pfizer, Inc, Boehringer Ingelheim Corporation, and UCB Pharma and has received grant support for studies/conferences from GlaxoSmithKline and Pfizer, Inc. Dr Rye has served as a consultant to Pfizer, Inc, Sepracor, Inc, GlaxoSmithKline, ACADIA Pharmaceuticals, and deCODE genetics and has received honoraria from GlaxoSmithKline and Cephalon, Inc. Drs Silber and Earley have no disclosures. ",
year = "2004",
month = jul,
doi = "10.4065/79.7.916",
language = "English (US)",
volume = "79",
pages = "916--922",
journal = "Mayo Clinic proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "7",
}